<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01417884</url>
  </required_header>
  <id_info>
    <org_study_id>TuePIC012011</org_study_id>
    <secondary_id>KFO 274/1-1</secondary_id>
    <nct_id>NCT01417884</nct_id>
  </id_info>
  <brief_title>Monocentric Registry to Investigate the Role of Platelet Function, Platelet Genetics, Proteomics and Metabonomics in Heart Disease</brief_title>
  <acronym>TuePIC</acronym>
  <official_title>Development of a Prospective Cardiovascular Patient Cohort and Biobank and Provision of Genomic Analyses With Focus on Platelet Function and Platelet Mediated Inflammatory Processes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart and Lung Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Molecular targets on platelets are pivotal for the development of new pharmacological
      substrates for platelet inhibition and to better understand the impact of platelet-mediated
      inflammatory processes for the progression of heart disease, such as coronary heart disease
      and chronic heart failure. Previous investigations on the thienopyridine Clopidogrel have
      underlined the importance of combined risk factor analysis. Thus, clopidogrel´s prognostic
      efficacy relies on the combination of genetic factors (mainly polymorphisms of CYP2C19
      encoding genes) and non-genetic factors, such as age, diabetes mellitus or concomitant drugs.
      Therefore, a prospective patient cohort with exact phenotypic characterisation according to
      standardized protocols is necessary to enable the examination of the clinical relevance of
      potential molecular targets. A supplementary provision of high quality bio-material enables
      the systematic examination of new promising platelet-biomarkers in cardiovascular disease,
      which already have produced significant results on experimental animal and/or cell biologic
      models. Primary objective of the central project is to establish a prospective cardiological
      cohort in the setting of a Cardiovascular Clinical Research Unit (CCRU) with an affiliated
      Biobank and thus to review the clinical significance of potential targets deriving from
      individual subprojects within the research group (German Research Council KFO 274/1-1) to
      safeguard a translational approach.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Death</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ischemic stroke</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>ischemic heart disease</arm_group_label>
    <description>stable coronary artery disease, acute coronary syndromes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-ischemic heart disease</arm_group_label>
    <description>inflammatory heart disease, heart failure (non-ischemic), valvular heart disease</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, salivatory
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In-hospital patients and outpatients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with ischemic and non-ischemic heart disease

          2. informed consent by patients or relatives in case of missing capacity to consent due
             to health status

        Exclusion Criteria:

          1. Patients &lt;18 years

          2. missing informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Geisler, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UKT</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthias Schwab, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UKT, IKP Stuttgart</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tobias Geisler, Prof. Dr.</last_name>
    <phone>+49 7071 29 83688</phone>
    <email>tobias.geisler@med.uni-tuebingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik Tübingen, Cardiology Department, University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2011</study_first_submitted>
  <study_first_submitted_qc>August 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2011</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Tobias Geisler</investigator_full_name>
    <investigator_title>Professor Dr. Tobias Geisler</investigator_title>
  </responsible_party>
  <keyword>molecular cardiology</keyword>
  <keyword>molecular epidemiology</keyword>
  <keyword>platelets</keyword>
  <keyword>cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

